ArticlePediatric nephrology (Berlin, Germany)2012
Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease.
Article in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Inflammatory bowel disease increases the levels of albuminuria and the risk of urolithiasis: a two-sample Mendelian randomization study.European journal of medical research · 2023Pooled it
- Renal manifestations in inflammatory bowel disease: a systematic review.Journal of gastroenterology · 2022Pooled it
- Renal lithiasis and inflammatory bowel diseases, an update on pediatric population.Acta bio-medica : Atenei Parmensis · 2018Pooled it
- Urinary biomarkers of urolithiasis risk in Crohn's disease: hyperoxaluria, hypocitraturia, and hypomagnesuria in patients with and without ileocolic resection.Crohn's & colitis 360 · 2026Article
- Urolithiasis in Children-Clinical Picture, Pathogenesis, and Diagnostic Approach.Biomolecules · 2026Review
- Risk profile of promoters and inhibitors of kidney stone formation in paediatric inflammatory bowel disease.Pediatric nephrology (Berlin, Germany) · 2025Article
- Hyperoxaluria: Diagnosis and Treatment.The Urologic clinics of North America · 2025Review
- OxDc-A0: an oral gastro-tolerant oxalate decarboxylase for treating secondary hyperoxaluria.Urolithiasis · 2025Article
- Intestinal Oxalate Absorption, Enteric Hyperoxaluria, and Risk of Urinary Stone Formation in Patients with Crohn's Disease.Nutrients · 2024Article
- Dietary advice for patients with bowel-related conditions and malabsorption.World journal of urology · 2023Review
- Pediatric Nephrolithiasis.Healthcare (Basel, Switzerland) · 2023Review
- Oxalate homeostasis.Nature reviews. Nephrology · 2023Review
- Oxalate as a potent promoter of kidney stone formation.Frontiers in medicine · 2023Review
- Chronic liver disease and hepatic calcium-oxalate deposition in patients with primary hyperoxaluria type I.Scientific reports · 2022Article
- [Nephrolithiasis and nephrocalcinosis in children and adolescents].Urologie (Heidelberg, Germany) · 2022Review
- The pathological and outcome characteristics of renal lesions in Crohn's disease.BMC nephrology · 2022Review
- Article
- An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria.Molecular systems biology · 2022Article
- Acute oxalate nephropathy: A potential cause of acute kidney injury in diabetes mellitus-A case series from a single center.Frontiers in medicine · 2022Article
- Case report: Acute oxalate nephropathy due to traditional medicinal herbs.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevalence of recurrent calcium-oxalate (CaOx) urolithiasis (UL) is up to fivefold higher in Crohn's disease than in the general population. Treatment options are scarce and the risk of recurrent UL or progressive renal CaOx deposition, (oxalosis) based early end-stage renal failure (ESRF), subsequent systemic oxalosis, and recurrence in the kidney graft is pronounced. We aimed to find proof that secondary hyperoxaluria is the main risk factor for the devastating course and correlates with intestinal oxalate absorption.
methods24-h urines were collected and analyzed for urinary oxalate (Uox) in 27 pediatric (6-18 years) and 19 adult patients (20-62 years). In the 21 patients (8 adults and 13 children) with hyperoxaluria a [(13)C(2)]oxalate absorption test was performed under standardized dietary conditions.
resultsMean Uox was significantly higher in patients with UL or oxalosis (0.92 ± 0.57) compared with those without (0.53 ± 0.13 mmol/1.73 m(2)/24 h, p<0.05, normal < 0.5). Hyperoxaluria then significantly correlated with intestinal oxalate absorption (p< 0.05).
conclusionAs UL/oxalosis has major implications for the general health in patients with Crohn's disease (ESRF and systemic oxalosis), new medication, e.g. to reduce intestinal oxalate absorption, is definitely needed.
Indexed as
Identifiers
22366809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.